Introduction: Patients presenting with new onset interstitial lung disease (ILD) should be assessed for secondary, potentially treatable, causes. Some patients with rheumatic disease may present with ILD as the first manifestation of their condition. Early diagnosis and treatment of an underlying rheumatic disease can improve patient outcome. As autoimmune screening has evolved to include extended myositis and scleroderma panels, increasing numbers of patients with ILD are being referred forreviewbyarheumatologist.Thiscasehighlightsone suchpatientdiagnosed with new onset ILD during an acute hospital admission but subsequently found to have anunderlying connective tissue disease (CTD). Case description: A 54-year-old previously fit and well man presented to the Emergency Department with a three-month history of progressively worsening shortness of breath and dry cough. He denied any other symptoms, including those in keeping with a connective tissue disease (CTD). His past medical history was unremarkable. His father had a possible diagnosis of Sjö gren's syndrome and his sister had Sjö gren's syndrome with ILD. He had a20 pack year smoking history. On admission his could only walk ten meters before having to stop due to shortness of breath. On auscultation of his chest he had fine inspiratory crepitations in the mid and lower zones. Blood tests revealed an elevated c-reactive protein (CRP) of 96 and erythrocyte sedimentation rate (ESR) of 120. He failed to improve with intravenous antibiotics and his CRP rose to 122. Computer tomography (HRCT) of the chest, abdomen and pelvis revealed bilateral reticulation peripherally in the mid and lower zones and paraseptal/centrilobular emphysematous changes in the upper zones. Pulmonary function tests (PFTs) demonstrated normal spirometry but reduced gas transfer. Anti-cyclic citrullinated peptide (anti-CCP) antibodies, rheumatoid factor, anti-neutrophil cytoplasmic antibodies (ANCA) and HIV screen were negative. Creatine kinase was normal. ANA was positive, with positive anti-Ro-52 antibodies and positive anti-PL12 onan extended myositis panel. A diagnosis of anti-synthetase syndrome was made. He was treated with three 1 gram doses of intravenous methylprednisolone on consecutive days then switched to 40mg of oral prednisolone daily. His inflammatory markers improved and he was discharged home. Monthly cyclophosphamide infusions werecommenced and he has received two doses thus far. Although subjectively the patient does not report much improvement in his breathing as yet, he attends his appointments independently and is able to walk over 50 meters without stopping. Repeat PFTs and HRCT chest are scheduled. Discussion: Patients presenting with ILD with no identifiable cause should be assessed and screened for CTDs. Evaluation should include a thorough history and examination, looking for associated conditions. ILD may be associated with rheumatoid arthritis, systemic sclerosis, polymyositis, dermatomyositis, anti-synthetase syndrome, sarcoidosis, Sjogren's syndrome, mixed connective tissue disease and systemic lupus erythematous (SLE). Pulmonary function tests may demonstrate a restrictive pattern on spirometry, although this can be normal. Gas transfer is often reduced and a carbon monoxide transfer factor of < 40% is indicative of advanced disease. Imaging, usually in the form of high-resolution CT (HRCT), can allow assessment of the pattern of ILD and the potential for reversibility. It can often help avoid the need for lung biopsy. If no clear alternative cause of ILD (eg. drugs, occupational exposure, inhaled substances, infection, radiation) then physicians should consider sending bloods to help excludes CTDs, including creatine kinase, rheumatoid factor, anti-CCP antibodies, anti-nuclear antibodies (with extended myositis and scleroderma panels) and ANCA,even in asymptomatic patients. Case series have demonstrated that ILD may be the only presenting feature in a proportion of those with anti-synthetase syndrome, particularly in patients with anti-PL7 or PL-12. The classic triad of clinical features for anti-synthetase syndrome consists of ILD, myositis and arthritis (mechanic's hands). Our patient had no CTD symptoms at presentation but has gone on to develop Raynaud's and stiffness in his fingers over the last 6 months. He has not at any stage had evidence of myositis, either clinically or serologically, which is in keeping with case series of patients with ILD and PL-12 positivity reporting a proportion as being amyopathic. Particular factors that should prompt screening for anti-synthetase syndrome include female gender, middle age, clinical signs suggestive of aCTD and an NSIP pattern onHRCT. Key learning points: Rheumatic conditions which can present with ILD include rheumatoid arthritis, systemic sclerosis, polymyositis, dermatomyositis, anti-synthetase syndrome, sarcoidosis, Sjö gren's syndrome, mixed connective tissue disease and SLE.Newly presenting ILD patients with no identifiable cause should be checked for rheumatoid factor, anti-CCP antibodies, anti-nuclear antibodies (with extended myositis and scleroderma panel) and ANCA. ILDassociated with anti-synthetase syndrome, polymyositis ordermatomyositis often warrants early treatment with steroid and cyclophosphamide oranother immunosuppressive agent suchas rituximab. Patient characteristics which should prompt screening for anti-synthetase syndrome with extended myositis panel testing include clinical suspicion of CTD, female gender, middle age, CTD symptoms or signs and NSIP pattern onHRCT. All patients presenting with ILD should have pulmonary function tests and imaging to assessseverity of disease. Conflicts of interest: The authors have declared no conflicts of interest.
28. ACUTE PULMONARY ARTERIAL HYPERTENSION IN PRIMARY SJÖ GREN'S SYNDROME WITH KNOWN CRYPTOGENIC ORGANISING PNEUMONIA Liora Wittner 1 , Mareen Joy 1 , and Spencer Ellis 1 1 Rheumatology, East and North Hertfordshire NHS Trust, Stevenage, United Kingdom Introduction: We describe the case of a 58-year-old female with a background of primary Sjö gren's syndrome (PSS) and cryptogenic organising pneumonia (COP), who recently presented with worsening of her breathlessness and reduced exercise tolerance. CT pulmonary angiogram (CTPA) ruled out pulmonary embolism (PE) and indicated an improvement in the radiological appearance of her COP. However, an echocardiogram suggested the development of significant pulmonary arterial hypertension (PAH), requiring specialist input for vasodilators, phosphodiesterase inhibitors, endothelin receptor antagonists and diuretics. This case highlights the importance of thoroughly investigating breathlessness in connective tissue disease (CTD) patients and the need to consider dual pathology. Case description: We report a case from 2019 involving a 58-year-old female who was already known to rheumatology with PSS, diagnosed in 2012. She was known to be ANA positive with anti-Ro and anti-La antibodies and had a history of anxiety. She was referred to the respiratory team in 2017, due to 6 months of progressive exertional breathlessness. A CT scan showed features consistent with COP, although lung function was considered to bestable, so notreatment was initiated. Prednisolone was commenced in November 2018, due to worsening breathlessness. Despite this she continued to deteriorate, and in February 2019 her exercise tolerance reduced significantly, with new ankle swelling and postural dizziness. Clinical examination demonstrated a raised JVP. CTPA was negative for pulmonary thromboembolism. An urgent echocardiogram showed a severely dilated right ventricle with impaired systolic function, severe tricuspid regurgitation and an estimated PASP of 81mmgHg, suggestiveof significant PAH. The patient was admitted but developed type 1 respiratory failure and was transferred to a specialist centre for right heart catheterisation, confirming PAH. The patient received intravenous epoprostenol, dopamine and furosemide. The admission was complicated by pyrexia of unknown origin despite prolonged antibiotics, with no microorganisms grown on blood or bronchoscopic cultures. CT chest showed new widespread ground glass changes. Her fevers settled after withdrawal of antimicrobials and she was discharged on oral selexipag, tadalafil, macitentan, furosemide and spironolactone. Her post discharge exercise tolerance is improved, and she has even been able to return to horse riding. Symptoms remain less severe than prior to her hospital admission, although worse than they had been as an inpatient on intravenous therapy; however, her oral medications are still being titrated. Right heart catheterisation, echocardiography and lung function tests will be repeated 4monthspost discharge. Discussion: PSS is not as strongly associated with severe organ involvement compared with other CTDs. At clinic reviews, clinicians tend to focus on dealing with sicca and joint symptoms and lymphoma monitoring. This case emphasises the importanceof screeningforandinvestigating respiratory symptoms, and the importance of considering PAH even when other lung diagnoses arepresent. The case demonstrated several potential causes for breathlessness: worsening COP, PAH and PE. She was diagnosed with COP 6 months after the onset of her sicca symptoms and had been stable until 3 months before presentation. She had regular pulmonary function tests to monitor progress under respiratory follow up. COP is a form of interstitial lung disease (ILD) which is thought to occur when alveolar epithelial injury ultimately results in intra-alveolar fibrosis. Radiological appearances include multiple patchy alveolar opacities which tend to be distributed peripherally and bilaterally. Opacities may appear like typical infective consolidation or have more of a ground glass appearance and may spontaneously migrate during the disease course, i30 27 September 2019 POSTER PRESENTATIONS meaning severity may be difficult to assess. Air bronchograms are often present.
When she was reviewed in clinic with worsening breathlessness, there was no evidence that her COP was worsening radiologically, and her breathlessness had not improved with prednisolone. CTPA had excluded chronic thromboembolic pulmonary hypertension; however, studies have shown that CTD patients with antiphospholipid antibodies are more likely to develop PAH, even in absence of thrombosis. Our patient was positive for cardiolipin IgG and IgM. Nonetheless, clinical suspicion was sufficient for the patient to have echocardiography which indicated new onset PAH. Her PAH was severe and symptomatic resulting in urgent admission to a specialist unit. This case highlights the key symptoms and signs which may make clinicians suspect PAH including reduced exercise tolerance and features of right heart failure. Key learning points: Pulmonary involvement in PSS is common and 10-20% of patients develop significant respiratory disease. COP, although a rare ILD in the context of PSS (more common in rheumatoid arthritis), should be suspected in Sjö gren's patients with radiological consolidation who donot respond to antibiotic treatment. The most common subtype of ILD in Sjö gren's is non-specific interstitial pneumonia (fibrosing variant). Along with COP, other less common manifestations include usual interstitial pneumonia and lymphocytic interstitial pneumonitis. These rarer manifestations of ILD are not as clearly identifiableradiologically and may require lungbiopsies. Studies suggest that the main risk factors for lung involvement include smoking, late onset and long evolution of disease. As in this case, pulmonary involvement is commonly associated with hypergammaglobulinaemia and anti-SSA, anti-SSB, ANA and rheumatoid factor positivity. We are not aware of many clinical or serological parameters which could be used to risk stratify whichPSS patients arelikely to develop ILD. PAHshouldbesuspected inpatientswithunderlyingCTDeven inthecontext of pre-existing lung disease such as ILD or COP. Studies suggest that up to 20% of primary Sjö gren's patients may have asymptomatic PAH, therefore PAH should be considered in patients who respond poorly to steroid treatment for suspected ILD. PAH is challenging, as by the time it progresses to symptoms it can be severe and even life threatening. Early diagnosis and appropriate referral to a specialist unit may be critical. Case description: Our patient is an 83-year-old lady who was referred to rheumatology. She has complex medical history of chronic suppurative lung disease with pseudomonas infection. In addition she had previous ESBL urinary tract infection (UTI), deep vein thrombosis and pulmonary embolism. Management of infection is severely limited by her multiple antibiotic intolerances (gentamycin, tobramycin, colomycin, fluoroquinolones, doxycycline, cefaclor, amoxicillin, co-amoxiclav, meropenem, tazobactam/piperallin and ceftazidime). She is on prophylactic cefradine for UTI and prophylacticamoxicillin forlung infection. On presentation, she had inflammatory polyarthritis which was subsequently diagnosed as seronegative rheumatoid arthritis (RA). She had limited therapeutic options owing to chronic suppurative lung disease. She was advised against methotrexate and leflunomide by chest physician. She could not tolerate sulfasalazine twice during the course of her illness due to gastrointestinal side effects and had to stop hydroxychloroquine because of headache and nausea. Therefore, she had to be managed with tapering doses of prednisolone and intraarticular knee injection during flairs.
Nearly two years after her first presentation, she developed recurrent headache. However, there were no other symptoms of giant cell arteritis.
On clinical examination her temporal arteries were prominent, thickened and tender to touch but pulsatile. CRP was 88. Ultrasound of temporal arteries showed evidence of inflammation. Biopsy of temporal artery was not performed. She was treated with prednisolone 20 mg daily. She continued treatment for six weeks and showed clinical improvement with normalization of CRP. Her prednisolone dose continued to be tapered successfully. However, she developed complications from treatment, in form of worsening cataract and recurrent urinary tract infections. At the time of article submission, her GCA and RA remain in remission while her prednisolone had been tapered to 9 mg daily. Discussion: Based on NICE guidelines, the treatment of GCA is 60mg of prednisolone for patients with visual symptoms and 40mg of prednisolone for patients without visual symptoms. The risk of infections in highdose glucocorticoids is well-established. A study using administrative data found that GCA patients, when compared with a matched historical cohort, had increased rates of lower respiratory tract infections, UTI, and other serious infections, which are defined as pneumonias, upper urinary tract infections, and sepsis. The rate of infection is the highest in the first six months of treatment during the greatest glucocorticoid exposure. Due to her pre-existing chronic suppurative lung disease, it was deemed to be of too high risk to commence on the standard dose of prednisolone and to adhere to the recommended length of tapering. We have decided to opt for a lower dose (20mg) of prednisolone for 6 weeks and taper after that. The dose was selected based on the risk and benefit assessment of her underlying chronic infection. There may be difficulties in future management because usual steroid-sparring agents (DMARDs and biologics) would becontra-indicated. According to NICE guidelines, the diagnosis of GCA should be confirmed on temporal artery biopsy (TAB). We have decided that the clinical and imaging evidences were sufficient to diagnose her GCA. We felt that temporal artery biopsy would not add or change her therapeutic management. Key learning points: This case highlights the difficulty in managing multiple inflammatory conditions in the presence of complex chronic infections. In case in which all recommended treatments are contraindicated, we have to be prepared to deviate from the recommended guidelines and make decisionbasedon patient tailored risk benefit assessment. This case also serves as a reminder of the importance of shared decisionmaking and multi-disciplinary approach in managing complex clinical case.She isatriskof developingcomplications fromprolonged glucocorticoid use, and therefore we have involved the local respiratory team and discussed the case in the rheumatology multi-disciplinary (MDT) meeting.
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THE PARADOX
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Introduction: Incidental findings on investigations is not uncommon in rheumatology practice. Here such an incidental finding has led to dramatic change in the management of the underlying disease. Case description: A 38-year-old gentleman known to have ankylosing spondylitis (AS) since 2008, with radiologically evident sacroilitis on X-ray and MRI, was reviewed routinely in clinic and reported pain and restriction of neck movement and subsequent MRI cervical spine in April 2017 has shown incidental finding of apical fibrosis, but noAS activity. He denied constitutional and respiratory symptoms apart from occasional dry cough. Chest X-ray and high resolution CT scan confirmed the same findings of apical fibrosis in addition to bilateral reticulonodular and fisural changes. Blood tests showed angiotensin converting Eezyme level ACE 65 U/L(normalrange 8-65), C-reactive protein <5. Bronchoscopy/biopsy showed non-caseating epitheliod granuloma. ZN stain and culture showed no TB infection. He was reviewed by the respiratory team and felt findings could conceivablyfit with sarcoidosis. His dry cough has improved after Benepali was discontinued in June 2017 and no steroids were given. However, had a flare of AS symptoms (ribs and lower back pain and stiffness,right SIJ pain) despite regularetoricoxib and required to start onsecukinumab. Discussion: Benepali (Etanercept biosimilar) sounds not different from the originator biologic in causing sarcoid-like reactions commonly
